Tech Transfer Roundup: MD Anderson Inks Set Of IO Deals Covering US, UK, Japan, China
Three separate agreements team the innovative cancer research center with Takeda, Artios/ShangPharma, and Ziopharm. Hoth continues busy deal-making year by licensing gene therapy from North Carolina State.
You may also be interested in...
TNX-1600 joins two other candidates, including Phase III TNX-102 SL, in Tonix’s PTSD portfolio. CureVac and Yale partner on mRNA therapies for pulmonary disease.
Five-year collaboration will analyze data from thousands of cancer patients to optimize immunotherapy treatment and develop PET imaging tracers to stratify clinical trial participants. Also, MD Anderson starts 2019 with three new agreements.
Joint prize for MD Anderson's James Allison and Kyoto University's Tasuku Honjo for checkpoint immunotherapy reflects decades of research and billions of IO dollars for industry.